TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive อ่านต่อไป

TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan อ่านต่อไป

TOKYO, Mar 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, อ่านต่อไป

TOKYO, Mar 23, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Corporation (MC) and Nippon Telegraph and Telephone Corporation (NTT) are pleased to announce their decision to establish a new joint venture company that will provide cross-industry Digital Transformอ่านต่อไป